These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 15703363)
21. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. Aweeka FT; Kang M; Yu JY; Lizak P; Alston B; Chung RT; HIV Med; 2007 Jul; 8(5):288-94. PubMed ID: 17561874 [TBL] [Abstract][Full Text] [Related]
22. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. Yan JH; Bifano M; Olsen S; Smith RA; Zhang D; Grasela DM; LaCreta F J Clin Pharmacol; 2006 Nov; 46(11):1250-8. PubMed ID: 17050790 [TBL] [Abstract][Full Text] [Related]
23. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Wu JZ; Larson G; Walker H; Shim JH; Hong Z Antimicrob Agents Chemother; 2005 Jun; 49(6):2164-71. PubMed ID: 15917509 [TBL] [Abstract][Full Text] [Related]
24. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Watson J Curr Opin Investig Drugs; 2002 May; 3(5):680-3. PubMed ID: 12090539 [TBL] [Abstract][Full Text] [Related]
25. Viramidine demonstrates better safety than ribavirin in monkeys but not rats. Dadgostari S; Xu C; Yeh LT; Lin CC; Vitarella D Drug Chem Toxicol; 2004 Aug; 27(3):191-211. PubMed ID: 15478943 [TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Wu LS; Rower JE; Burton JR; Anderson PL; Hammond KP; Baouchi-Mokrane F; Everson GT; Urban TJ; D'Argenio DZ; Kiser JJ Antimicrob Agents Chemother; 2015 Apr; 59(4):2179-88. PubMed ID: 25645847 [TBL] [Abstract][Full Text] [Related]
28. Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Kamar N; Chatelut E; Manolis E; Lafont T; Izopet J; Rostaing L Am J Kidney Dis; 2004 Jan; 43(1):140-6. PubMed ID: 14712437 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic evaluation of (-)-6-aminocarbovir as a prodrug for (-)-carbovir in rats. Zimmerman CL; Remmel RP; Ibrahim SS; Beers SA; Vince R Drug Metab Dispos; 1992; 20(1):47-51. PubMed ID: 1346995 [TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Lertora JJ; Rege AB; Lacour JT; Ferencz N; George WJ; VanDyke RB; Agrawal KC; Hyslop NE Clin Pharmacol Ther; 1991 Oct; 50(4):442-9. PubMed ID: 1680594 [TBL] [Abstract][Full Text] [Related]
31. Influence of pre-analytical conditions on plasma ribavirin concentrations. Gandia P; Trancart S; Nicot F; Barange K; Alric L; Izopet J; Séraissol P; Lavit M; Houin G Arzneimittelforschung; 2010; 60(10):636-9. PubMed ID: 21125815 [TBL] [Abstract][Full Text] [Related]
33. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232 [TBL] [Abstract][Full Text] [Related]
34. The clinical pharmacology of ribavirin. Glue P Semin Liver Dis; 1999; 19 Suppl 1():17-24. PubMed ID: 10349689 [TBL] [Abstract][Full Text] [Related]
35. Ribavirin in the treatment of hepatitis C. Abonyi ME; Lakatos PL Anticancer Res; 2005; 25(2B):1315-20. PubMed ID: 15865084 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects. O'Farrell AM; van Vliet A; Abou Farha K; Cherrington JM; Campbell DA; Li X; Hanway D; Li J; Guler HP Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550 [TBL] [Abstract][Full Text] [Related]
37. Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. Li L; Koo SH; Limenta LM; Han L; Hashim KB; Quek HH; Lee EJ J Clin Pharmacol; 2009 Jun; 49(6):661-7. PubMed ID: 19369574 [TBL] [Abstract][Full Text] [Related]
38. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Morello J; Rodríguez-Nóvoa S; Cantillano AL; González-Pardo G; Jiménez I; Soriano V Ther Drug Monit; 2007 Dec; 29(6):802-6. PubMed ID: 18043479 [TBL] [Abstract][Full Text] [Related]
39. Effect of ibuprofen on lithium plasma and red blood cell concentrations. Kristoff CA; Hayes PE; Barr WH; Small RE; Townsend RJ; Ettigi PG Clin Pharm; 1986 Jan; 5(1):51-5. PubMed ID: 3948485 [TBL] [Abstract][Full Text] [Related]
40. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. Wong SL; Barriere SL; Kitt MM; Goldberg MR J Antimicrob Chemother; 2008 Oct; 62(4):780-3. PubMed ID: 18586659 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]